Listen on the go
CORRECT!
Next question
touchDERMATOLOGY touchDERMATOLOGY

Start Learning

Touch Loading image
CONFERENCE HUB
Start Learning
Amit G. Pandya, Dermatology Meeting News 2023: Efficacy & safety of ruxolitinib cream in vitiligo – findings from the TRuE-V phase 3 studies
Recent content from our partner site touchIMMUNOLOGY
CONFERENCE HUB
Start Learning
Type 2 inflammatory skin diseases – relieving itch: Raj Chovatiya
CONFERENCE HUB
Start Learning
OLYMPIA 2: nemolizumab improves prurigo nodularis-associated pain and patient reported outcomes: Adam Reich
CONFERENCE HUB
Start Learning
Gil Yosipovitch, EADV 2022: LIBERTY-PN-PRIME Study – Dupilumab for the Treatment of Prurigo Nodularis Recent content from our partner site touchIMMUNOLOGY
CONFERENCE HUB
Start Learning
Phase III SUNSHINE and SUNRISE trials investigating secukinumab in hidradenitis suppurativa: Afsaneh Alavi
CONFERENCE HUB
Start Learning
Luis Felipe C. Ensina, AAAAI 2023: Ligelizumab for the treatment of chronic spontaneous urticaria – findings from PEARL-1 and PEARL-2
Recent content from our partner site touchIMMUNOLOGY
CONFERENCE HUB
Start Learning
Remibrutinib in chronic spontaneous urticaria patients: phase 3b extension trial: Marcus Maurer, EAACI 2023
Recent content from our partner site touchIMMUNOLOGY
Thierry passeron EADV
CONFERENCE HUB
Start Learning
Analysis of global non-melanoma skin cancer incidence and mortality: Thierry Passeron
JOURNALS
Start Learning
Bruton Tyrosine Kinase Inhibitors in Chronic Spontaneous Urticaria: A Focus on Remibrutinib
CONFERENCE HUB
Start Learning
Lupus erythematosus – exploring new insights and emerging therapies: Victoria Werth

to view Favourites, Keep Notes and Track CME Credits

Favourites
What to Know About the Addition of Janus Kinase Inhibitors to the Dermatologist’s Armamentarium
View
The Role of Ixekizumab in Palmoplantar Psoriasis | Insights from AAD 2023
View
Amit G. Pandya, Dermatology Meeting News 2023: Efficacy & safety of ruxolitinib cream in vitiligo – findings from the TRuE-V phase 3 studies
Recent content from our partner site touchIMMUNOLOGY
View
Victoria P. Werth: The phase 3 DeterMine trial of lenabasum in dermatomyositis Recent content from our partner site touchIMMUNOLOGY
View
Navigating the emerging complexities of melanoma treatment: New insights for clinical practice
View
Raj Chovatiya, Dermatology Meeting News 2023: Efficacy & safety profile of baricitinib for inflammatory dermatologic disease
Recent content from our partner site touchIMMUNOLOGY
View
William Damsky, Dermatology Meeting News 2023: A personalised approach to treating inflammatory skin diseases
Recent content from our partner site touchIMMUNOLOGY
View
Upadacitinib in a phase 2 study of adults with non-segmental vitiligo: Thierry Passeron
View
Remibrutinib in chronic spontaneous urticaria patients: phase 3b extension trial: Marcus Maurer, EAACI 2023
Recent content from our partner site touchIMMUNOLOGY
View
Vaccination and the antibiotic landscape of cutaneous sexually transmitted infections: Georg Stary
View
Copied to clipboard!
accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72